Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma

• Status: Completed
• Trial end date: 2018-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy of orally administered propranolol versus atenolol in the treatment of potentially disfiguring or functionally threatening IHs.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: West China Hospital
• Treatments: Atenolol; Propranolol

Criteria

Inclusion Criteria:

• Patients younger than 24 weeks.

• Presenting a hemangioma with the following characteristics:

• Subcutaneous and/or cutaneous

• Minimum diameter of 1.5 cm on face, 3 cm outside face and 1.5 cm if it is ulcerated.

• Consent of both parents (or the person having parental authority in families)

Exclusion Criteria:

• Infant presenting contraindications for the administration of propranolol or atenolol.

• Hemangioma has been previous treated with corticosteroids, laser, cryotherapy, or only other treatments.

• Patients with an inability to participate or to follow the study treatment and assessment plan.